TORONTO, Aug. 11, 2017 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF; FSE:3D0) (the "Company" or
"3DS"), announces that Helen Stevenson has resigned as a director of the Company effective immediately.
3DS wishes to thank Ms. Stevenson for her contribution, and wishes her all the best in her future endeavors.
The Company will take steps to fill Ms. Stevenson’s vacated seat as soon as practicable.
About 3DS
3DS (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) is a personalized medicine company with a proprietary software platform
based on the three-dimensional analysis of chromosomal signatures. The technology is well developed and supported by 22 clinical
studies on over 2,000 patients on 13 different cancers and Alzheimer’s disease. Depending on the desired application, this platform
technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is
designed to predict the course of disease and to personalize treatment for the individual patient. For more information, visit the
Company’s website at http://www.3dsignatures.com.
Forward-Looking Information
This news release includes forward-looking statements, such as the Company’s intention to fill vacancies on
its board of directors, that are subject to risks and uncertainties. Forward-looking statements involve known and unknown risks,
uncertainties, and other factors that could cause the actual results of the Company to be materially different from the historical
results or from any future results expressed or implied by such forward-looking statements. All statements within, other than
statements of historical fact, are to be considered forward looking. Although 3DS believes the expectations expressed in such
forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual
results or developments may differ materially from those in forward-looking statements. Risk factors that could cause actual
results or outcomes to differ materially from the results expressed or implied by forward-looking information include, among other
things: market demand; technological changes that could impact the Company’s existing products or the Company’s ability to
develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the
failure to comply with, governmental legislation and regulations; the ability to manage operating expenses, which may
adversely affect the Company’s financial condition; the Company’s ability to successfully maintain and enforce its intellectual
property rights and defend third-party claims of infringement of their intellectual property rights; adverse results or
unexpected delays in clinical trials; changes in laws, general economic and business conditions; and changes in the regulatory
regime. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on
their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking
statements.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information, please contact: Jason Flowerday CEO & Director 604-428-8842 investors@3dsignatures.com
